Racial disparity in taxane‐induced neutropenia among cancer patients

Background Large interindividual variations have been reported in chemotherapy‐induced toxicities. Little is known whether racial disparities exist in neutropenia associated with taxanes. Methods Patients with a diagnosis of primary cancer who underwent chemotherapy with taxanes were identified from...

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) MA), 2021-10, Vol.10 (19), p.6767-6776
Main Authors: Zheng, Neil S., Wang, Fei, Agarwal, Rajiv, Carroll, Robert J., Wei, Wei‐Qi, Berlin, Jordan, Shu, Xiao‐Ou
Format: Article
Language:English
Subjects:
Age
Aged
Body mass index
Cancer
Cancer therapies
Chemotherapy
Clinical Cancer Research
Codes
Electronic health records
Female
healthcare disparities
Healthcare Disparities - trends
Humans
Laboratories
Leukocytes (neutrophilic)
Male
Middle Aged
neoplasms
Neoplasms - blood
Neoplasms - drug therapy
Neoplasms - pathology
Neutropenia
Neutropenia - chemically induced
Neutrophils
Paclitaxel
Patients
Race
Race Factors
Radiation therapy
Regression analysis
Taxanes
Taxoids - adverse effects
Terminology
Variables
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Large interindividual variations have been reported in chemotherapy‐induced toxicities. Little is known whether racial disparities exist in neutropenia associated with taxanes. Methods Patients with a diagnosis of primary cancer who underwent chemotherapy with taxanes were identified from Vanderbilt University Medical Center's Synthetic Derivative. Multinomial regression models were applied to evaluate odds ratios (ORs) and 95% confidence intervals (CIs) of neutropenia associated with race, with adjustments for demographic variables, baseline neutrophil count, chemotherapy‐related information, prior treatments, and cancer site. Results A total of 3492 patients were included in the study. Compared with White patients, grade 2 or higher neutropenia was more frequently recorded among Black patients who received taxanes overall (42.2% vs. 32.7%, p 
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.4181